Login to Your Account



Financings NEWS
Rare disease specialist Atyr Pharma Inc. has completed a $76 million series E financing that it will use to further develop and advance its pipeline, led by an ongoing phase Ib/II trial of Resolaris (ATYR-1940) for patients with facioscapulohumeral muscular dystrophy (FSHD).
Multivir Inc., a Houston-based gene therapy company taking a second swing at two adenovirus-based cancer therapies – one of which drove Introgen Therapeutics Inc. to bankruptcy – has filed to raise up to $70 million in a proposed IPO that will support the first part of phase I/II trials of both candidates.
Aiming to step beyond the almost voodoo-like guesswork that's characterized drug development in the space, Allergen Research Corp. (ARC) plans a phase III trial with lead compound AR101 in peanut allergy.
More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: